Blueshift Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Blueshift Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$466K	Buy	+8,143	New	+$446K	0.11%	234
2025 Q3	–	Sell	-10,792	Closed	-$593K	–	458
2025 Q2	$593K	Buy	+10,792	New	+$635K	0.18%	149
2025 Q1	–	Sell	-5,314	Closed	-$349K	–	405
2024 Q4	$349K	Buy	+5,314	New	+$356K	0.13%	223
2022 Q4	–	Sell	-2,523	Closed	-$214K	–	372
2022 Q3	$214K	Buy	+2,523	New	+$225K	0.05%	496
2022 Q2	–	Sell	-8,243	Closed	-$636K	–	700
2022 Q1	$636K	Buy	+8,243	New	+$690K	0.06%	365
2021 Q2	–	Sell	-10,455	Closed	-$789K	–	930
2021 Q1	$789K	Buy	+10,455	New	+$854K	0.08%	331

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Blueshift Asset Management's BMRN Position: Q2 2026 in Review

Blueshift Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 8,143 shares worth $466K. The stake represents 0.11% of the portfolio and ranks #234 among its holdings. This is a return to the name: Blueshift Asset Management previously reported a position in BMRN as recently as Q2 2025.

Blueshift Asset Management first reported a position in BMRN in Q1 2021 and has held it in 6 quarters since. The position peaked at $789K in Q1 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Blueshift Asset Management held 8,143 shares of BioMarin Pharmaceuticals worth $466K as of Q2 2026.
BioMarin Pharmaceuticals was a new Blueshift Asset Management position in Q2 2026.
BioMarin Pharmaceuticals made up 0.11% of Blueshift Asset Management's portfolio in Q2 2026, its #234 holding.
Blueshift Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and has held it in 6 quarters since.
Blueshift Asset Management's BioMarin Pharmaceuticals position peaked at $789K in Q1 2021.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.